21.08.2012 - Sanofi withdraws a cancer drug from the markets and aims for a relaunch in multiple sclerosis.
Sanofi is withdrawing its cancer drug Campath from the markets. The pharma plans to commercialise the antibody under a different name and dosing regime for multiple sclerosis – a much more lucrative indication.
The development of Campath-1H, also known under its generic name alemtuzumab, as a successful drug took years. The anti-CD52 antibody was thought to cure rheumatoid arthritis in the beginning of the 90s but failed expectations. Since 2001, it has finally been approved for chronic lymphocytic leukaemia (CLL). Since then it also washes some money into Sanofi’s subsidiary Genzyme Corp. from Cambridge (USA). But revenues have been decling over the past years. Therefore Sanofi is now aiming for fresh money and a higher pricing. In a move to prevent off-label use the drug has now been pulled from European (in mid-August) and US markets (in early September) markets.
In both regions the market authorisation applications (MAAs) for a use in multiple sclerosis are pending. According to the pharma company clearing the market should ensure that „alemtuzumab is exclusively received and used in the ongoing clinical trials.“ Obviously, Sanofi thinks that a widely merchandised drug could jeopardise these trials. Alemtuzumab awaits its repeated market entry under the name Lemtrada. However, the German society for haematology and oncology (DGHO) criticises Sanofi for playing one group of patients against another. Sanofi responded that all leukaemia patients (so far about 4.000) will benefit from free-of-charge programmes that make sure that all patients receive their much needed medicine. In Germany, according to the DGHO, these programmes run so far quite smoothly even if they mean an increased bureaucratic effort.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more